1-3 of 3
Samuel Yamshon, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Samuel Yamshon, MD, Peter Martin, FRCPC, MD MS, Bijal Shah, MD, Stephen J. Schuster, MD, Paul J Christos, Dr.P.H., M.S., Amelyn Rodriguez, BSN, RN, OCN, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Sarah C. Rutherford, MD, John N. Allan, MD, John P. Leonard, MD, Jia Ruan, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-138731
Published: 2020
Journal Articles

Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a Subset

Samuel Yamshon, MD, Miguel Dario Cantu, Ethel Cesarman, MD PhD, Sarah C. Rutherford, MD, Amy Chadburn, MD, Genevieve Marie Crane, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2792.
https://doi.org/10.1182/blood-2019-128374
Published: 2019
Journal Articles

Venous Thromboembolism in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Lenalidomide

Samuel Yamshon, MD, Michelle Demetres, BA, Hoda Hammad, MS, MPH, Paul J Christos, Dr.P.H., M.S., John P. Leonard, MD, Jia Ruan, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 221.
https://doi.org/10.1182/blood.V130.Suppl_1.221.677
Published: 2017